Civil Rights Division Security Controls Audit and CRT-JCON System

The DOJ Office of Inspector General released Audit Report 26-045 assessing the Civil Rights Division's security controls and the CRT-Justice Consolidated Office Network (CRT-JCON) system under the Federal Information Security Modernization Act of 2014 for Fiscal Year 2025. The audit identifies deficiencies in security controls and provides recommendations for remediation. Federal agencies should review the findings to assess whether similar control gaps exist within their own systems.

Civil Rights Division Information Security Management Program Audit (FISMA)

The DOJ Office of Inspector General issued Audit Report 26-044 examining the Civil Rights Division's information security management program under the Federal Information Security Modernization Act of 2014 (FISMA) for Fiscal Year 2025. The audit identified 4 recommendations for improvement. This is a routine compliance assessment of a federal government component's IT security posture, not an enforcement action.

AnalYTE SENSORS AND METHODS OF USE THEREOF

The USPTO published Abbott Diabetes Care Inc.'s patent application (US20260090745A1) for analyte sensors capable of detecting biological analytes using multiple enzyme systems. Inventors Zenghe Liu and Benjamin J. Feldman developed the disclosed technology for medical diagnostic applications.

Devices and Methods for Body Fluid Sampling and Analysis

The USPTO published patent application US20260090746A1 for meters and methods for sampling, transporting, and analyzing body fluid samples. The invention includes a meter housing with imaging system, a cartridge with sampling arrangements, and skin-penetration members for fluid collection. Application filed May 8, 2025, by inventors Raul Escutia et al.

Eye Tracking Machine Learning System for Physiological Assessment

RightEye LLC filed USPTO patent application US20260090750A1 for a system using eye tracking and machine learning to automatically assess physiological states. The invention captures eye movement data, processes it through an ML model trained to identify patterns associated with physiological characteristics, and outputs both the physiological state and recommended interventions. Application No. 19343212 was published April 2, 2026.

Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies

USPTO published patent application US20260090529A1 disclosing transgenic non-human animals that produce modified heavy chain-only antibodies (HCAbs). The invention involves substituting the native amino acid residue at the first position of framework region FR4 with a different residue to disrupt a surface-exposed hydrophobic patch, potentially improving antibody characteristics. Named inventors include Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, and Mike Osborn.

Micronized Antibodies in Polymeric Particles for Drug Delivery

USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.

Self-assembling peptide gel for tissue lift, repair

The USPTO published patent application US20260091159A1 by Norchi et al. disclosing compositions containing self-assembling peptides that form stable in situ gels for tissue lift, repair, and bulking applications. The formulations are designed for use during endoscopic, laparoscopic, or open surgical procedures and provide hemostatic properties with adhesion prevention for periods of days to one month.

Metastatic cancer treatment using abscopal effect with radiotherapy

The USPTO published patent application US20260091085A1 assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising type 1 interferon combined with low-dose radiotherapy to induce systemic anticancer effects (abscopal effect) in metastatic cancer sites. The application claims a method where administering type 1 interferon with low-dose radiation to the primary tumor site produces anticancer effects at non-radiated metastatic sites.

Amylin Receptor Agonist and GLP-1 Receptor Agonist Combination Therapy

USPTO published patent application US20260091086A1 for a combination therapy comprising amylin receptor agonists and GLP-1 receptor agonists. The application, filed on May 19, 2025, covers polypeptide combinations for therapeutic uses including weight management (A61P 3/04). Invented by Sarah WILL, the application represents a potential new approach to metabolic disorder treatment.